3-11 Primrose Avenue
Rosebery, NSW 2018
61 2 9381 1000
|Dr. Karen Annette Duggan||CEO & Exec. Director||229.93k||N/A||N/A|
|Mr. Robert John Waring BEc, CA, FAICD, FCIS, FFin||Company Sec.||N/A||N/A||N/A|
|Prof. Graham Jon MacDonald AM, BS, BSc (Med), FANZCC, FRACP, FRCP, M.D.||Consultant||N/A||N/A||N/A|
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure, which include treatments for heart, kidney, liver, and lung diseases. Its lead compound is VB0004, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops AccuCal and RealCount software that enhance speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was incorporated in 2005 and is based in Rosebery, Australia.
Vectus Biosystems Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.